Core Viewpoint - Baipusais (301080.SZ) plans to issue H-shares and list on the Hong Kong Stock Exchange to further promote its internationalization strategy [1] Company Overview - Baipusais focuses on the biotechnology sector, primarily engaged in the research, production, and sales of biopharmaceuticals, aiming to provide high-quality biological products and services for the healthcare industry [3] - The company is involved in innovative applications of biotechnology, with its main products and services targeting early drug discovery and validation, drug screening and optimization, diagnostic reagent development, preclinical and clinical trials, and process control in drug production [3] Financial Performance - For the first three quarters of 2025, Baipusais reported a revenue of 613 million yuan, representing a year-on-year increase of 32.3% [3] - The net profit attributable to the parent company was 132 million yuan, up 58.6% year-on-year, while the net profit excluding non-recurring items was 133 million yuan, reflecting a 58.8% increase [3] - The net operating cash flow reached 177 million yuan, showing a significant growth of 99.5% year-on-year, with an earnings per share (EPS) of 0.789 yuan [3]
新股消息 | 百普赛斯拟港股IPO 前三季度营收超6亿元